Xilio Therapeutics (XLO) Net Cash Flow (2020 - 2026)

Xilio Therapeutics has disclosed Net Cash Flow across 7 years of filings, most recently posting -$14.3 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 143.98% year-over-year to -$14.3 million; the TTM figure through Jun 2026 stood at $14.5 million (down 68.87% YoY), while the FY2025 annual figure was $82.3 million, up 662.98% from the prior year.
• Net Cash Flow came in at -$14.3 million for Q2 2026 at Xilio Therapeutics, down from $12.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $40.0 million in Q2 2024 to a low of -$27.1 million in Q1 2023.
• Average Net Cash Flow over 5 years is -$3.4 million, with a median of -$14.7 million recorded in 2023.
• Year-over-year, Net Cash Flow jumped 666.57% in 2025 and sank 143.98% in 2026.
• Over 5 years, Net Cash Flow stood at -$18.8 million in 2022, then increased by 19.69% to -$15.1 million in 2023, then soared by 60.42% to -$6.0 million in 2024, then jumped by 666.57% to $33.8 million in 2025, then sank by 142.3% to -$14.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$14.3 million in Q2 2026, $12.8 million in Q1 2026, and $33.8 million in Q4 2025.